What would happen if we approached antibiotic resistance with the same fervor that we have for covid? Is there a reason why we should not?
Dr. David Shlaes
As an anti-coronavirus therapy, Remdesivir has been rather disappointing. That's primarily because the drug is given intravenously to those who are already very ill with COVID-19. But what would happen if the drug could be delivered directly to the lungs, to prevent severe disease? Gilead is giving it a shot. Here are some of the pros and cons of that approach.
Everyone take a deep breath and relax. During these crazy times, people are making all kinds of wild predictions about what drug or vaccine will work. Dr. David Shlaes takes a sobering look at the chances for any of these therapies to work. It's not as easy as you'd think. We should all lower our expectations a bit.
The United States is not the only country where drug pricing is disjointed. Referring to Europe, ACSH advisor Dr. David Shlaes writes that it is "definitely still a tapestry of nations or even the Wild West." Especially in the world of antibiotics.
Antibiotic resistance is spotty. If you are hospitalized in New York and you acquire a Gram-negative infection in the hospital, there is a reasonable chance it will be caused by a highly resistant pathogen. If you go to a hospital in New Hampshire or Vermont, there is almost no chance for that to happen. ACSH advisor Dr. David Shlaes explains.
The development of new antibiotics is as much about money as it is about science. ACSH advisor Dr. David Shlaes writes about biotechs, IPOs, disappointed investors, market cap, and CEO egos.
Antibiotics expert Dr. David Shlaes has been fighting two very tough fights for more than three decades. One is against increasingly dangerous antibiotic-resistant bacteria; the other, against complacency. This American Council advisor is deeply concerned that antibiotic research and development is not even remotely adequate for keeping up with the bugs.
It's indisputable that we need to develop new antibiotics – and fast. It's also all-but-indisputable that once this gets into the hands of politicians, they will screw it up. They sure did this time. American Council advisor Dr. David Shlaes explains.
Dr. David Shlaes, American Council advisor and infectious disease expert, has been blogging about antibiotics since 2009. His latest entry concerning the FDA is rather encouraging, but it's also a bit disturbing.
Back in May, the British government sponsored a review, headed up by former Goldman Sachs chief economist Jim O'Neill, regarding solutions to the antibiotic resistance crisis. O Neill s final report suggested that we de-link profits fr
We at ACSH have been writing about the dire situation we face because of antibiotic resistance for years. Both Dr. Josh Bloom and ACSH advisor Dr. David Shlaes a world renowned expert in the field have written many times about the looming antibiotic crisis, a time when common infections that were previously treatable are no longer so
The federal government took another small step in the battle to combat antibiotic-resistant bacteria. In the same week the WHO released a statement on the growing global crisis of antibiotic